(Recasts; adds details)
Oct 27 (Reuters) - Barr Pharmaceuticals Inc BRL.N said the U.S. regulators approved an oral contraceptive made by its unit Duramed Pharmaceuticals Inc.
Barr, which agreed to be bought by Israel-based Teva Pharmaceutical Industries Ltd TEVA.O for $7.46 billion in July, said the drug, LoSeasonique, would be available by prescription to women in the first quarter of 2009. The drug’s extended-cycle regimen, indicated for prevention of pregnancy, is designed to reduce the number of withdrawal bleeding periods from 13 to four per year, the company said in a statement.
Withdrawal bleeding is experienced each month when a woman uses a hormonal birth control method.
Shares of Barr were down 56 cents at $58.58 in early morning trade on the New York Stock Exchange. (Reporting by Esha Dey in Bangalore; Editing by Anil D‘Silva;)